拡大する精神治療薬市場

INTRODUCTION

STUDY GOAL AND OBJECTIVES

The objectives of the study are to present a comprehensive look at disorders that affect the mind. An overall discussion of mental health is presented along with an in-depth discovery of the various diseases and disorders that present significant problems for individuals and society. Markets are divided according to drug type because several products are used in many different disorders.

REASONS FOR DOING THIS STUDY

This BBC study is presented to highlight the exciting area of mental health. Because in-depth study of the workings of the brain is a fairly new area of intense study, there are new and changing theories. The discovery of new mechanisms and chemicals in the brain has provided additional avenues for research and development of products that may alter the course of the diseases or modify the outcome. This study analyzes the current psychotherapeutics and explores the new psychotherapeutics that are in the pipeline to treat mental disorders. The study also addresses the many and varied issues and trends affecting the market. Manufacturers have increased the pace of research and development for psychotherapeutic products fueled by demand for new and better compounds to treat psychological disorders. Because of the rapidly evolving climate of psychological disorders and the increasing knowledge of the workings of the brain, manufacturers of psychotherapeutics must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.

SCOPE OF STUDY

The report is designed to be a comprehensive business tool to provide an in-depth look at the fascinating world of mental health. The geographic scope of the report is global with an emphasis on the United States. The report identifies the different disorders in mental health; gives an explanation of the disorders; cites incidence; identifies specific drug types; presents current treatments, market size and market participants; and presents potential treatments in research and development. The report describes the industry in detail, its relationship to the healthcare industry and healthcare reform, its participants, and its trends for the future. Within the Market for Prescription Psychotherapeutic Drugs, the following markets are evaluated:

• Prescription Central Nervous System Depressants and Antianxiety Drugs
• Prescription Central Nervous System Antidepressant Drugs
• Prescription Central Nervous System Antimanic Drugs
• Prescription Central Nervous System Antipsychotic Drugs
• Prescription Central Nervous System Stimulant Drugs
• Prescription Central Nervous System Cholinesterase Inhibitor and Miscellaneous Alzheimer Treatment Drugs
• Prescription Central Nervous System Substance Abuse Treatment Drugs

All markets are further broken down into specific types of products that are discussed in detail, measuring current and potential market size, identifying current and potential market drivers, forecasting for 2002 and 2007, assessing current and potential competitors and identifying current competitor market shares.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary executives, product managers, clinical specialists and doctors involved in mental health and psychotherapeutics. Industry experts' perspectives as well as company reports were used in the market analysis. Background information was obtained from various government, business, medical journal and trade magazines. Key information from published literature was used to conduct interviews with over 85 industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and /or adjust market size and market share estimates, as well as formulating market projections.

TABLE OF CONTENTS

• STUDY GOALS AND OBJECTIVES
• REASONS FOR STUDY
• SCOPE OF STUDY
• METHODOLOGY AND INFORMATION SOURCES
• ANALYST CREDENTIALS
• RELATED BCC REPORTS
• BCC ONLINE SERVICES
• INTERNET
• DISCLAIMER

• Summary Table:
  GLOBAL AND U.S. TOTAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Summary Figure:
  GLOBAL AND U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

• HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY
• HISTORICAL PERSPECTIVE (CONTINUED)
• HISTORICAL PERSPECTIVE (CONTINUED)
• HISTORICAL PERSPECTIVE (CONTINUED)
• HISTORICAL PERSPECTIVE (CONTINUED)
• HISTORICAL PERSPECTIVE (CONTINUED)
• HISTORICAL PERSPECTIVE (CONTINUED)
• HISTORICAL PERSPECTIVE (CONTINUED)
• INTRODUCTION TO THE NERVOUS SYSTEM AND BRAIN
• BLOOD-BRAIN BARRIER
• MENTAL HEALTH DISORDERS
  • Alzheimer’s Disease
• Table 1 MAJOR CAUSES OF PROGRESSIVE DEMENTIA (%)
  • Alzheimer’s Disease (Continued)
  • Alzheimer’s Disease (Continued)
  • Alzheimer’s Disease (Continued)
  • Alzheimer’s Disease (Continued)
• Table 2 PHARMACOLOGIC MANAGEMENT OF ALZHEIMER’S DISEASE
  • Anxiety Disorders
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Panic Disorder (Continued)
  • Post-traumatic Stress Disorder
  • Specific and Social Phobias
• Table 3 CLINICAL NAMES FOR COMMON PHOBIAS
  • Attention Deficit Hyperactivity Disorder
  • Bipolar Disorder
  • Bipolar I Disorder
  • Bipolar II Disorder
  • Cyclothymic Disorder
  • Borderline Personality Disorder
  • Borderline Personality Disorder (Continued)
  • Depression
  • Depression (Continued)
  • Eating Disorders
  • Anorexia Nervosa
  • Bulimia Nervosa
  • Obsessive-Compulsive Disorder
  • Schizophrenia
  • Schizophrenia (Continued)
  • Schizophrenia (Continued)
  • Sleep Disorders
  • Insomnia
  • Narcolepsy
  • Restless Legs Syndrome
  • Parasomnia
  • Parasomnia (Continued)
  • Substance Abuse-related Disorders
  • Substance Abuse-related Disorders (Continued)
  • Alcohol Abuse
  • Drug Abuse
  • DEMOGRAPHICS
• Table 4 ESTIMATED INCIDENCE/PREVALENCE OF CONDITIONS, 2000 (THOUSANDS)
  • PRESCRIBING TRENDS
  • PEDIATRIC AND ADOLESCENT USE
  • PRESCHOOLER USE
  • PHARMACEUTICAL TESTING IN CHILDREN
  • COST
    • Cost (Continued)
  • REIMBURSEMENT ISSUES
    • Reimbursement Issues (Continued)
  • LEGISLATIVE ACTIONS
    • Legislative Actions (Continued)
  • ELDERLY IMPACT
    • Elderly Impact (Continued)
    • Elderly Impact (Continued)
    • Elderly Impact (Continued)
    • Elderly Impact (Continued)
    • Elderly Impact (Continued)
  • PSYCHIATRIC PHARMACOGENETICS
  • PATENT ISSUES AND GENERIC PARTICIPATION
• Table 5 PATENT EXPIRATION FOR SELECTED PRESCRIPTION PSYCHOTHERAPEUTICS 2002
  • COMPLIANCE ISSUES
    • Compliance Issues (Continued)
    • Compliance Issues (Continued)
    • Compliance Issues (Continued)
  • INTERNET ADDICTION—FACT OR FICTION
  • GENETIC LINK TO MULTIPLE DISORDERS
  • PSYCHIATRIC DISEASES ON THE RISE
    • Psychiatric Diseases on the Rise (Continued)
  • MENTAL HEALTH AGENDA SETTING—ANOTHER VIEW
    • Mental Health Agenda (Continued)
    • Mental Health Agenda (Continued)
    • Mental Health Agenda (Continued)
  • HEALTHCARE REFORM
    • Healthcare Reform (Continued)
  • PRESCRIPTION CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS
  • OVERVIEW
  • MARKETED PRODUCTS
    • Barbiturates
    • Benzodiazepines
    • Miscellaneous Central Nervous System Depressants and Antianxiety Drugs
  • MARKET SIZE AND FORECAST
• Table 6 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 1 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 7 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 2 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 8 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)
• Figure 3 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)
  • PRODUCTS IN THE PIPELINE
• Table 9 PRESCRIPTION CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS IN DEVELOPMENT 2002
  • Products in the Pipeline (Continued)
  • COMPETITIVE ANALYSIS
• Table 10 GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002
• Figure 4 CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUG MANUFACTURER PERCENTAGE MARKET SHARE BY REVENUES, 2002
  • PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS
  • OVERVIEW
  • MARKETED PRODUCTS
    • Monoamine Oxidase Inhibitors
    • Selective Serotonin Reuptake Inhibitors
    • Selective Serotonin Reuptake Inhibitors (Continued)
    • Tricyclic Antidepressants
    • Miscellaneous Antidepressants
    • Miscellaneous Antidepressants (Continued)
  • MARKET SIZE AND FORECAST
• Table 11 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 5 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 12 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 6 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 13 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)
• Figure 7 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)
  • PRODUCTS IN THE PIPELINE
• Table 14 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS IN DEVELOPMENT 2002
  • Products in the Pipeline (Continued)
  • COMPETITIVE ANALYSIS
• Table 15 CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002
• Figure 8 CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)
  • PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS
  • OVERVIEW
  • MARKETED PRODUCTS
    • Lithium
    • Miscellaneous Antimanic Drugs
  • MARKET SIZE AND FORECAST
• Table 16 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 9 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 17 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 10 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 18 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)
• Figure 11 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)
  • PRODUCTS IN THE PIPELINE
• Table 19 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS IN DEVELOPMENT 2002
  • COMPETITIVE ANALYSIS
• Table 20 CENTRAL NERVOUS SYSTEM ANTIMANIC DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002
• Figure 12 CENTRAL NERVOUS SYSTEM ANTIMANIC DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002
  • PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS
  • OVERVIEW
  • MARKETED PRODUCTS
    • Phenothiazines and Combinations
    • Miscellaneous Antipsychotic Agents
  • MARKET SIZE AND FORECAST
• Table 21 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 13 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 22 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 14 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 23 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)
• Figure 15 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)
  • PRODUCTS IN THE PIPELINE
• Table 24 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS IN DEVELOPMENT, 2002
  • COMPETITIVE ANALYSIS
• Table 25 CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002
• Figure 16 CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002
  • PRESCRIPTION CENTRAL NERVOUS SYSTEM STIMULANT DRUGS
  • OVERVIEW
  • MARKETED PRODUCTS
    • Amphetamines
    • Miscellaneous Central Nervous System Stimulants
  • MARKET SIZE AND FORECAST
• Table 26 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 17 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 27 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 18 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 28 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)
• Figure 19 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)
  • PRODUCTS IN THE PIPELINE
• Table 29 PRESCRIPTION CENTRAL NERVOUS SYSTEM STIMULANT DRUGS IN DEVELOPMENT, 2002
  • COMPETITIVE ANALYSIS
• Table 30 CENTRAL NERVOUS SYSTEM STIMULANT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002
• Figure 20 CENTRAL NERVOUS SYSTEM STIMULANT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)
  • PRESCRIPTION CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS
  • OVERVIEW
  • MARKETED PRODUCTS
  • MARKET SIZE AND FORECAST
• Table 31 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 21 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 32 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 22 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 33 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER’S DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)
• Figure 23 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER’S DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)
  • PRODUCTS IN THE PIPELINE
• Table 34 PRESCRIPTION CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITORS AND ALZHEIMER TREATMENT DRUGS IN DEVELOPMENT, 2002
• Table 34 (CONTINUED)
  • COMPETITIVE ANALYSIS
• Table 35 CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002
• Figure 24 CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)
  • PRESCRIPTION CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS
    • OVERVIEW
    • MARKETED PRODUCTS
    • MARKET SIZE AND FORECAST
• Table 36 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 25 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 37 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 26 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
• Table 38 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)
• Figure 27 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)
  • PRODUCTS IN THE PIPELINE
• Table 39 PRESCRIPTION CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS IN DEVELOPMENT, 2002
  • COMPETITIVE ANALYSIS
• Table 40 CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002
• Figure 28 CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)
  • TOTAL MARKET SUMMARY
  • INDUSTRY STRUCTURE
  • GLOBAL MARKET FOR PSYCHOTHERAPEUTIC DRUGS
• Table 41 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 29 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
  • GLOBAL MARKET PERCENTAGE BY PRODUCT TYPE
• Table 42 GLOBAL MARKET PERCENT FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS BY CATEGORY, 2002
  • U.S. MARKET FOR PSYCHOTHERAPEUTIC DRUGS
• Table 43 U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)
• Figure 30 U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)
  • U.S. MARKET PERCENTAGE BY PRODUCT TYPE
• Table 44 U.S. MARKET PERCENT FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS BY CATEGORY, THROUGH 2007
  • TOTAL COMPETITIVE STRUCTURE AND MARKET SHARE
• Table 45 TOTAL CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG COMEPTITIVE MARKET, 2002
• Figure 31 TOTAL CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG COMEPTITIVE MARKET, 2002 (%)
  • INDUSTRY PARTICIPANTS BY PRODUCT TYPE
• Table 46 CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG MANUFACTURERS BY PRODUCT TYPE, 2002
• Table 46 (CONTINUED)
  • COMPETITIVE STRATEGIES BASED ON PRODUCTS
  • COMPANY PROFILES
  • ABBOTT LABORATORIES
  • ASTRAZENECA PLC
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY & COMPANY
  • FOREST LABORATORIES, INC.
  • GLAXOSMITHKLINE PLC
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • NOVARTIS INTERNATIONAL AG
  • ORGANON INTERNATIONAL, INC.
  • PFIZER, INC.
  • PHARMACIA CORP.
  • SANOFI-SYNTHELABO
  • SHIRE PHARMACEUTICALS GROUP PLC
  • WYETH
  • Wyeth (Continued)

• LIST OF COMPANIES
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)

LIST OF TABLES

Summary Table:
GLOBAL AND U.S. TOTAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 1 MAJOR CAUSES OF PROGRESSIVE DEMENTIA (%)

Table 2 PHARMACOLOGIC MANAGEMENT OF ALZHEIMER’S DISEASE

Table 3 CLINICAL NAMES FOR COMMON PHOBIAS

Table 4 ESTIMATED INCIDENCE/PREVALENCE OF CONDITIONS, 2000 (THOUSANDS)

Table 5 PATENT EXPIRATION FOR SELECTED PRESCRIPTION PSYCHOTHERAPEUTICS 2002

Table 6 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 7 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 8 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)

Table 9 PRESCRIPTION CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS IN DEVELOPMENT 2002

Table 10 GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002

Table 11 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 12 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 13 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)

Table 14 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS IN DEVELOPMENT 2002

Table 15 CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002

Table 16 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 17 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 18 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)

Table 19 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS IN DEVELOPMENT 2002

Table 20 CENTRAL NERVOUS SYSTEM ANTIMANIC DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002

Table 21 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 22 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 23 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)

Table 24 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS IN DEVELOPMENT, 2002

Table 25 CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002

Table 26 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 27 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 28 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)

Table 29 PRESCRIPTION CENTRAL NERVOUS SYSTEM STIMULANT DRUGS IN DEVELOPMENT, 2002

Table 30 CENTRAL NERVOUS SYSTEM STIMULANT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002

Table 31 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 32 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 33 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER’S DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)

Table 34 PRESCRIPTION CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITORS AND ALZHEIMER TREATMENT DRUGS IN DEVELOPMENT, 2002

Table 35 CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002

Table 36 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 37 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 38 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 (%)

Table 39 PRESCRIPTION CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS IN DEVELOPMENT, 2002

Table 40 CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002

Table 41 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 42 GLOBAL MARKET PERCENT FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS BY CATEGORY, 2002

Table 43 U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, THROUGH 2007 ($ MILLIONS)

Table 44 U.S. MARKET PERCENT FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS BY CATEGORY, THROUGH 2007

Table 45 TOTAL CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG COMEPTITIVE MARKET, 2002

Table 46 CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG MANUFACTURERS BY PRODUCT TYPE, 2002  

LIST OF FIGURES

Summary Figure:
GLOBAL AND U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 1 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 2 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 3 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)

Figure 4 CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUG MANUFACTURER PERCENTAGE MARKET SHARE BY REVENUES, 2002

Figure 5 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 6 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 7 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)

Figure 8 CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)

Figure 9 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 10 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 11 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)

Figure 12 CENTRAL NERVOUS SYSTEM ANTIMANIC DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002

Figure 13 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 14 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 15 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)

Figure 16 CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002

Figure 17 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 18 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 19 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)

Figure 20 CENTRAL NERVOUS SYSTEM STIMULANT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)

Figure 21 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 22 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 23 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER’S DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)

Figure 24 CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)

Figure 25 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 26 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 27 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 (%)

Figure 28 CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)

Figure 29 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 30 U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 2000-2007 ($ MILLIONS)

Figure 31 TOTAL CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG COMEPTITIVE MARKET, 2002 (%)